Antibody Drug Conjugates Contract Market: Myeloma Is Expected To Be The Highest ( Us$ 29.7 Bn ) Revenue-Generating Condition Type | Fact.MR
30 Jun 2022
CollaborateGene TherapyAntibodyVaccineADC
The Antibody Drug Conjugates Contract industry revenues were valued at US$ 8.1Bn in 2021 and have been predicted to grow at a CAGR of 15.5% from 2022-2032, according to a recently published Fact.MR report. By the end of 2032, the market is expected to cross the value of US$ 39 Bn.
During the historical period of 2015-2021, the market segment for cleavable linkers expanded at a CAGR of 12.6 %, and it is predicted to increase at a CAGR of 17.2 percent during the forecasted period of 2022-2032.
Antibody-drug conjugates are a type of biopharmaceutical used to treat cancer that consists of an antibody that targets a tumor antigen specifically a cytotoxic substance linked by a chemical linker. They're designed to allow the cytotoxic substance to be precisely targeted to kill tumor cells while causing minimal damage to healthy tissue. Because ADCs are a new class of biopharmaceuticals, their development necessitates are both chemical and biological expertise. Technical expertise in conjugation and linker development, as well as robust platforms, are provided by contract manufacturing companies.
For more insights into the Market, Get A Sample of this Report!
APAC Antibody-Drug Conjugates Contract Is Developing Due To The Rising Frequency of Cancer
The Asia Pacific led the antibody-drug conjugates contract manufacturing market with a 46.4 %revenue share in 2020. The Asia Pacific accounts for 48% of all new cancer cases worldwide. Out of all the cases, China holds nearly half of the sufferers.
The market for APAC antibody-drug conjugates contract is developing due to the rising frequency of cancer and the growing geriatric population. According to Globocan Data 2020, 52 % of cancer patients are 65 or older, and by 2040, this number is expected to quadruple. The most frequent cancer in China is lung cancer, which is followed by stomach, liver, colon, rectum, and breast cancers.
Key Takeaways from the Market Study
Antibody Drug Conjugates Contract market is expected to cross the market value of US$ 9.2 Bn by 2022.
The Asia Pacific is anticipated to be the most lucrative region in terms of growth.
Myeloma to be the most successful condition type with the expected CAGR of 17% CAGR in the next 10 years.
US with US$ 7.3 Bn anticipated market value in 2032 to be the most promising revenue generating country.
Competitive Landscape
A number of regional and global players operate in this market. These companies compete based on the innovation of their products, their quality, their brand reputation, and their market presence in order to sell their products through various industries. A variety of strategies are being employed by companies to remain competitive.
In January 2022, Merck and ID Pharma Signed a Memorandum of Understanding to Accelerate Gene Therapy Development and Manufacturing.
In December 2021, Merck announced that it has joined forces with Innovative Biotech to support the establishment of Nigeria's first vaccine manufacturing facility.
In July 2021, Recipharm signed a Memorandum of Understanding (MOU) for the fill-finish of vaccines and biotherapeutics in Morocco.
Get Report Customization As Per Your Requirements
Some of the recent developments of Antibody Drug Conjugates Contract Market providers are as follows:
In January 2022, Recipharm announced the purchase of GenIbet to expand its biologics platform.
In August 2021, Recipharm announced that it has opened a new laboratory to boost its analytical services.
In July 2021, Lonza Group has extended its relationship with a large biopharmaceutical sector client for the supply of an antibody-drug conjugate against hard-to-treat malignancies.
In September 2020, Merck announced a EUR 59 million expansion of its ADC manufacturing capabilities at its Wisconsin site. This investment is likely to enable the large-scale production of increasingly effective chemicals for cancer therapy.
Market Segments Covered in Antibody Drug Conjugates Contract Market Industry Analysis
By Condition Type
Myeloma
Lymphoma
Breast Cancer
Other Condition Types
By Application
Cleavable Linker
Non-cleavable Linker
By Region
North America
Latin America
Europe
APAC
MEA
More Insights Available
Fact.MR, in its new offering, presents an unbiased analysis of the Antibody Drug Conjugates Contract market, presenting historical market data (2015-2021) and forecast statistics for the period of 2022-2032.
The study reveals essential insights on the basis of condition type (Myeloma, Lymphoma, Breast Cancer and other Condition Types) and Application (Cleavable Linker and Non-cleavable Linker) across five regions (North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa).
Questionnaire answered in the Antibody Drug Conjugates Contract Market report include:
How the market for Antibody Drug Conjugates Contract Market has grown?
What is the present and future outlook of the global Antibody Drug Conjugates Contract Market on the basis of region?
What are the challenges and opportunities for the Antibody Drug Conjugates Contract Market?
Why the consumption of Antibody Drug Conjugates Contract Market highest in region?
In which year segment is expected to overtake segment?
Fact.MR’s Domain Expertise in Healthcare Sector
Our Healthcare consulting team guides organizations at each step of their business strategy by helping you understand how the latest influencers account for operational and strategic transformation in the healthcare sector. Our expertise in recognizing the challenges and trends impacting the global healthcare industry provides indispensable insights and support – encasing a strategic perspective that helps you identify critical issues and devise appropriate solutions.
Healthcare Contract Research Organization Market - As per Fact.MR’s report, from 2015 to 2021, demand for healthcare contract research organization market surpassed US$ 40 Bn by the end of 2021. According to the report, the market flourished at a CAGR of 5.2% during the aforementioned historical period.
Biotechnology & Pharmaceutical Services Outsourcing Market - The global biotechnology and pharmaceutical services outsourcing market garnered US$ 65 Bn in 2021, expanding at a historical CAGR of 4.2%. The outsourcing services help in overcoming trade barriers and help the organizations to enter international markets.
Electronic Health Records Market Study - New expansion activities, product approvals, product launches, partnerships, and acquisitions have positively impacted the EHR market in recent years. Furthermore, there has been a significant increase in the demand for electronic health records due to the growing digitalization which in turn is fueling the market growth.
Clear Aligners Market Study - Global sales of Clear Aligners in 2021 was held at US$ 3.2 Bn. With 32.4%, the projected market growth during 2022 - 2032 is expected to be significantly higher than the historical growth.
Endoscopy Devices Market Study - Global sales of Endoscopy Devices Market in 2021 was held at US$ 44.8 Bn. With 9.0%, the projected market growth during 2022 - 2032 is expected to be significantly higher than the historical growth.
About Us:
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
Mahendra Singh
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
Email: sales@factmr.com
Tel: +1 (628) 251-1583
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.